Claims
- 1. A pyridine derivative or a pharmacologically acceptable salt thereof expressed by the following formula 1: ##STR18## wherein W represents a group expressed by the following formula 2 or formula 3: ##STR19## wherein R.sub.1 represents an alkenyloxy group; n represents 1 or 2; each of R.sub.2 and R.sub.3 represents a hydrogen atom, a lower alkyl group, a lower alkoxy group, or a halogenated alkyl group; Ra represents a lower alkyl; and Rb represents a halogen atom; Y represents a group expressed by --NH-- or --CONH--; m represents an integer of 0 to 2, wherein when Y is --NH--, m is 1 or 2; and p represents 1.
- 2. A pyridine derivative or a pharmacologically acceptable salt thereof according to claim 1, wherein n is 1 and R.sub.1 is bonded to para-position of an amide group.
- 3. A pyridine derivative or a pharmacologically acceptable salt thereof according to claim 1, wherein n is 2.
- 4. A pyridine derivative or a pharmacologically acceptable salt thereof according to claim 1, which expressed by the following formula 5. ##STR20## wherein R.sub.1, R.sub.2, R.sub.3, Y, and m are same as those in the above-mentioned formula 1.
- 5. A pyridine derivative or a pharmacologically acceptable salt thereof according to claim 4, wherein Y is a group expressed by --NH--.
- 6. A pyridine derivative or a pharmacologically acceptable salt thereof according to claim 4, wherein R.sub.1 is bonded to para-position.
- 7. A pyridine derivative or a pharmacologically acceptable salt thereof according to claim 1, wherein R.sub.1 is prenyloxy group or geranyloxy group.
- 8. An anti-ulcer composition comprising, as an effective ingredient, a pyridine derivative or a pharmacologically acceptable salt thereof according to claim 1, together with a pharmaceutically acceptable carrier and/or adjuvant.
- 9. An antibacterial composition for inhibiting the growth of Helicobacter pyroli comprising, as an effective ingredient, a pyridine derivative or a pharmacologically acceptable salt thereof according to claim 1, together with a pharmaceutically acceptable carrier and/or adjuvant.
- 10. A method for the treatment of peptic ulcers in man or mammals in need of said treatment, which comprises administering an effective amount of a pyridine derivative or a pharmacologically acceptable salt thereof according to claim 1 to a host.
- 11. A method according to claim 10, wherein said peptic ulcers are gastric ulcers in man.
- 12. A method for the inhibition of acid secretion in stomach of man or mammals, which comprises administering an effective amount of a pyridine derivative or a pharmacologically acceptable salt thereof according to claim 1 to a host.
- 13. A method for the inhibition of growth of Helicobacter pyroli in stomach of man or mammals, which comprises administering an effective amount of a pyridine derivative or a pharmacologically acceptable salt thereof according to claim 1 to a host.
- 14. A method for treating of peptic ulcers in man or mammals in need of said treatment, which comprises administering an effective amount of a pyridine derivative or a pharmacologically acceptable salt thereof according to claim 1 to a host.
- 15. A method according to claim 14, wherein said peptic ulcers are gastric ulcers in man.
- 16. A pyridine derivative and a pharmacologically acceptable salt thereof according to claim 1, wherein said alkenyloxy group of R.sub.1 comprises a straight or branched alkenyl group having at least one double bond with 2 to 20 carbon atoms.
- 17. A pyridine derivative and a pharmacologically acceptable salt thereof according to claim 16, wherein said alkenyloxy group of R.sub.1 is selected from the group consisting of geranyloxy, prenyloxy, neryloxy, and farnesyloxy.
Priority Claims (2)
Number |
Date |
Country |
Kind |
8-90625 |
Mar 1996 |
JPX |
|
9-69166 |
Mar 1997 |
JPX |
|
Parent Case Info
This is a divisional application of U.S. patent application No. 08/818,281 (filed on Mar. 17, 1997) now U.S. Pat. No. 5,859,032.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4916145 |
Tilley et al. |
Apr 1990 |
|
5340827 |
Beeley et al. |
Aug 1994 |
|
5340828 |
Graham et al. |
Aug 1994 |
|